129 related articles for article (PubMed ID: 16461762)
1. Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma.
Younes A; Pro B; Fayad L
Blood; 2006 Feb; 107(4):1731-2. PubMed ID: 16461762
[No Abstract] [Full Text] [Related]
2. The role of bortezomib in the treatment of lymphoma.
Barr P; Fisher R; Friedberg J
Cancer Invest; 2007 Dec; 25(8):766-75. PubMed ID: 18058474
[TBL] [Abstract][Full Text] [Related]
3. Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma.
Vogl DT; Stadtmauer EA; Richardson PG; Sonneveld P; Schuster MW; Irwin D; Facon T; Harousseau JL; Boral A; Neuwirth R; Anderson KC
Br J Haematol; 2009 Nov; 147(4):531-4. PubMed ID: 19725827
[TBL] [Abstract][Full Text] [Related]
4. Tissue microarray analysis reveals protein expression patterns and potential biomarkers of clinical benefit to bortezomib in relapsed/refractory non-Hodgkin lymphoma.
Gerecitano J; Gounder S; Teruya-Feldstein J; Arcila M; Ogilvie S; Gonzalez C; Lin D; Zheng J; Zhang Z; McDonald A; Mulligan G; O'Connor OA
Br J Haematol; 2012 Jul; 158(2):290-292. PubMed ID: 22533368
[No Abstract] [Full Text] [Related]
5. Bortezomib retreatment in relapsed multiple myeloma - results from a retrospective multicentre survey in Germany and Switzerland.
Hrusovsky I; Emmerich B; von Rohr A; Voegeli J; Taverna C; Olie RA; Pliskat H; Frohn C; Hess G
Oncology; 2010; 79(3-4):247-54. PubMed ID: 21372599
[TBL] [Abstract][Full Text] [Related]
6. Family haploidentical donor-derived cytokine-induced killer cell biotherapy combined with bortezomib in two patients with relapsed multiple myeloma in a non-allogeneic transplant setting.
Zhou X; Zhu J; Sun H; Shao L; Xu M; Guo H
Leuk Lymphoma; 2013 Jan; 54(1):209-11. PubMed ID: 22734810
[No Abstract] [Full Text] [Related]
7. Bortezomib may be safely combined with Y-90-ibritumomab tiuxetan in patients with relapsed/refractory follicular non-Hodgkin lymphoma: a phase I trial of combined induction therapy and bortezomib consolidation.
Roy R; Evens AM; Patton D; Gallot L; Larson A; Rademaker A; Cilley J; Spies S; Variakojis D; Gordon LI; Winter JN
Leuk Lymphoma; 2013 Mar; 54(3):497-502. PubMed ID: 22906230
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib in combination with IGEV chemotherapy regimen for a primary refractory Hodgkin's lymphoma of bone.
Ding L; Wang HX; Xue M; Zhu L; Liu J; Yan HM; Duan LN; Wang ZD
Leuk Res; 2009 Sep; 33(9):e170-2. PubMed ID: 19403168
[No Abstract] [Full Text] [Related]
9. Bortezomib salvage therapy in refractory acute adult T-cell leukemia/lymphoma.
Hourigan CS; Forde PM; Ambinder RF; Gladstone DE
Leuk Lymphoma; 2013 Nov; 54(11):2563-4. PubMed ID: 23445368
[No Abstract] [Full Text] [Related]
10. Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation.
Bruno B; Patriarca F; Sorasio R; Mattei D; Montefusco V; Peccatori J; Bonifazi F; Petrucci MT; Milone G; Guidi S; Giaccone L; Rotta M; Fanin R; Boccadoro M; Corradini P;
Haematologica; 2006 Jun; 91(6):837-9. PubMed ID: 16769588
[TBL] [Abstract][Full Text] [Related]
11. New developments with bortezomib in treating multiple myeloma.
Reddy GK
Clin Lymphoma; 2004 Mar; 4(4):215-6. PubMed ID: 15072611
[No Abstract] [Full Text] [Related]
12. Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG).
Conconi A; Martinelli G; Lopez-Guillermo A; Zinzani PL; Ferreri AJM; Rigacci L; Devizzi L; Vitolo U; Luminari S; Cavalli F; Zucca E
Ann Oncol; 2011 Mar; 22(3):689-695. PubMed ID: 20810546
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib induces clinical remission and reduction of ADAMTS13 inhibitory antibodies in relapsed refractory idiopathic thrombotic thrombocytopenic purpura.
Mazepa MA; Raval JS; Moll S; Ma A; Park YA
Br J Haematol; 2014 Mar; 164(6):900-2. PubMed ID: 24345005
[No Abstract] [Full Text] [Related]
14. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.
Fisher RI; Bernstein SH; Kahl BS; Djulbegovic B; Robertson MJ; de Vos S; Epner E; Krishnan A; Leonard JP; Lonial S; Stadtmauer EA; O'Connor OA; Shi H; Boral AL; Goy A
J Clin Oncol; 2006 Oct; 24(30):4867-74. PubMed ID: 17001068
[TBL] [Abstract][Full Text] [Related]
15. Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma.
Di Bella N; Taetle R; Kolibaba K; Boyd T; Raju R; Barrera D; Cochran EW; Dien PY; Lyons R; Schlegel PJ; Vukelja SJ; Boston J; Boehm KA; Wang Y; Asmar L
Blood; 2010 Jan; 115(3):475-80. PubMed ID: 19965689
[TBL] [Abstract][Full Text] [Related]
16. Optimizing bortezomib treatment in patients with relapsed multiple myeloma.
Richardson P
Clin Adv Hematol Oncol; 2006 May; 4(5):4-5; discussion 8; suppl 13. PubMed ID: 16832859
[No Abstract] [Full Text] [Related]
17. Bortezomib, thalidomide, and dexamethasone for relapsed multiple myeloma: add it up and wait.
Badros A; Gahres N
Clin Adv Hematol Oncol; 2005 Dec; 3(12):916-7; discussion 918. PubMed ID: 16555432
[No Abstract] [Full Text] [Related]
18. Patterns of relapse or progression after bortezomib-based salvage therapy in patients with relapsed/refractory multiple myeloma.
Ahn JS; Jung SH; Yang DH; Bae SY; Kim YK; Kim HJ; Lee JJ
Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):389-94. PubMed ID: 24630919
[TBL] [Abstract][Full Text] [Related]
19. Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma.
Zangari M; Guerrero J; Cavallo F; Prasad HK; Esseltine D; Fink L
Haematologica; 2008 Jun; 93(6):953-4. PubMed ID: 18515882
[No Abstract] [Full Text] [Related]
20. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.
Petrucci MT; Giraldo P; Corradini P; Teixeira A; Dimopoulos MA; Blau IW; Drach J; Angermund R; Allietta N; Broer E; Mitchell V; Bladé J
Br J Haematol; 2013 Mar; 160(5):649-59. PubMed ID: 23293914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
